State Medicaid Pharmacy and Therapeutics Committee
General Information
- Government Type
- State Agency
- Entity
- Department of Health and Human Services (DHHS)
- Public Body
- Pharmacy and Therapeutics Committee
Notice Information
- Notice Title
- State Medicaid Pharmacy and Therapeutics Committee
- Notice Tags
- Medicaid, Pharmacies
- Notice Type(s)
- Meeting
- Event Start Date & Time
- December 17, 2015 07:15 AM
- Event End Date & Time
- December 17, 2015 08:45 AM
- Event Deadline Date & Time
- 12/10/15 06:00 PM
- Description/Agenda
- AGENDA Utah Department of Health Pharmacy and Therapeutics Committee Thursday, December 17, 2015 7:15 a.m. to 8:45 a.m. Cannon Health Building Room 128 Please note that persons who wish to address the P&T Committee may contact Bryan S. Larson at (bslarson@utah.gov) at least 7 calendar days prior to the meeting. Comments from visitors, while welcome, will be limited to 3 minutes due to time constraints. 1) Welcome and Introductions - Clinton Sheffield, MD, Chair a) Review and Approval of Minutes b) Housekeeping 2) DUR Board Update - Robyn Seely, PharmD 3) December Review - Vicki Frydrych, PharmD a) Opioid Induced Constipation i) Methylnaltrexone, Naloxegol b) Other States Report - Bryan S. Larson, PharmD i) Public Comment (A) Astra Zeneca - Sushma M. Patel, PharmD ii) Board Discussion/Questions iii) Board Action 4) Next Meeting January 21, 2016 (PCSK-9 Inhibitors) 5) Adjourned - Clinton Sheffield, MD, Chair Public comment that responds to the materials presented by the College of Pharmacy @University of Utah is most helpful. The foundation documents used for most reviews are prepared by the Oregon Evidence-based Practice Center or the University of Utah, College of Pharmacy, and are posted in advance on the P&T Committee website. Manufacturers are requested to submit any additional materials they would like reviewed as part of the process to: Dr. Gary Oderda College of Pharmacy 30 South 2000 East SLC, UT 84112-5820 All materials must be clearly labeled that they are submitted for consideration as part of the state of Utah Medicaid Preferred Drug List Program review process. Materials must be received at least 60 days before the scheduled review date. Materials most useful to support the evidence-based process include any new evidence (information from clinical trials or studies when possible) after the Oregon monograph was prepared, unpublished materials the company would like considered as part of the process, or any other materials not likely to be included in a literature search. Tentative 2015/2016 Pharmacy & Therapeutics Committee Schedule Month Topic Agents 12/17/2015 Opioid Induced Lubiprostone Constipation Methylnaltrexone Naloxegol, and other laxatives 1/21/2016 Proprotein Convertase Alirocumab Subltilisin Kexin Type 9 Evolocumab (PCSK9) Inhibitors
- Notice of Special Accommodations (ADA)
- NOTICE OF SPECIAL ACCOMMODATION DURING PUBLIC MEETINGS In compliance with the Americans with Disabilities Act, individuals needing special accommodations (including auxiliary communicative aids and services) during this meeting should notify Lisa Hunt at 801-538-6317.
- Notice of Electronic or Telephone Participation
- N/A
Meeting Information
- Meeting Location
-
288 North 1460 West
Cannon Health Building _ Room 128
Salt Lake City, 84116
Show in Apple Maps Show in Google Maps - Contact Name
- Ngan Huynh
- Contact Email
- nganhuynh@utah.gov
- Contact Phone
- 801-538-6155
Notice Posting Details
- Notice Posted On
- December 07, 2015 05:02 PM
- Notice Last Edited On
- December 07, 2015 05:02 PM
- Deadline Date
- December 10, 2015 06:00 PM
Download Attachments
| File Name | Category | Date Added |
|---|---|---|
| 11.15.P&T.Nov.Minutes.pdf | Meeting Minutes | 2015/12/17 04:39 PM |
Subscribe
Subscribe by Email
Subscription options will send you alerts regarding future notices posted by this Body.